The DOI matches its Crossref record; 185 of the 185 references it cites were found in a registry or an index.
Glutamate as a therapeutic target in psychiatric disorders
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Glycine potentiates the NMDA response in cultured mouse brain neurons
Johnson, J. W., & Ascher, P. (1987) · Nature · doi:10.1038/325529a0 · Cited by 3,139
Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus
Malberg, J. E., Eisch, A. J., Nestler, E. J., & Duman, R. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-24-09104.2000 · Cited by 3,111
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Self-citationMemantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
McEwen, B. S. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02950-4 · Cited by 1,827
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685
Neuropsychological Function in Schizophrenia: Selective Impairment in Memory and Learning
Saykin, A. J. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810310036007 · Cited by 1,155
d -Serine is an endogenous ligand for the glycine site of the N -methyl- d -aspartate receptor
Mothet, J.-P., Parent, A. T., Wolosker, H., Brady, R. O., Linden, D. J., Ferris, C. D., Rogawski, M. A., & Snyder, S. H. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.9.4926 · Cited by 1,137
Mice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia
Mohn, A. R., Gainetdinov, R. R., Caron, M. G., & Koller, B. H. (1999) · Cell · doi:10.1016/s0092-8674(00)81972-8 · Cited by 1,075
NMDA receptor hypofunction model of schizophrenia
Olney, J. W., Newcomer, J. W., & Farber, N. B. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00029-1 · Cited by 1,020
Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats
Moghaddam, B., & Adams, B. W. (1998) · Science · doi:10.1126/science.281.5381.1349 · Cited by 1,006
Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia
Lahti, A. (1995) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00131-i · Cited by 921
Neuropsychology of First-Episode Schizophrenia: Initial Characterization and Clinical Correlates
Bilder, R. M., Goldman, R. S., Robinson, D., Reiter, G., Bell, L., Bates, J. A., Pappadopulos, E., Willson, D. F., Alvir, J. M. J., Woerner, M. G., et al. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.549 · Cited by 906
Chumakov, I., Blumenfeld, M., Guerassimenko, O., Cavarec, L., Palicio, M., Abderrahim, H., Bougueleret, L., Barry, C., Tanaka, H., La Rosa, P., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412499 · Cited by 829
Wolosker, H., Blackshaw, S., & Snyder, S. H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13409 · Cited by 811
Morris, R. (1989) · The Journal of Neuroscience · doi:10.1523/jneurosci.09-09-03040.1989 · Cited by 771
Pharmacologic effects of CI‐581, a new dissociative anesthetic, in man
Domino, E. F., Chodoff, P., & Corssen, G. (1965) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt196563279 · Cited by 748
Malhotra, M. D. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00036-5 · Cited by 680
D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia
Tsai, G. E., Yang, P., Chang, Y.-C., & Chong, M.-Y. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.032 · Cited by 674
Effects of Ketamine in Normal and Schizophrenic Volunteers
Lahti, A. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00243-3 · Cited by 674
A unified model of NMDA receptor-dependent bidirectional synaptic plasticity
Shouval, H. Z., Bear, M. F., & Cooper, L. N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152343099 · Cited by 607
Ketamine-Induced NMDA Receptor Hypofunction as a Model of Memory Impairment and Psychosis
Newcomer, J. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00067-0 · Cited by 604
Umbricht, D., Schmid, L., Koller, R., Vollenweider, F. X., Hell, D., & Javitt, D. C. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.12.1139 · Cited by 583
Self-citationD-serine added to antipsychotics for the treatment of schizophrenia
Tsai, G., Yang, P., Chung, L.-C., Lange, N., & Coyle, J. T. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00279-0 · Cited by 571
The Glutamatergic Dysfunction Hypothesis for Schizophrenia
Coyle, J. T. (1996) · Harvard Review of Psychiatry · doi:10.3109/10673229609017192 · Cited by 568
Moghaddam, B. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb13387.x · Cited by 567
Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments
Krystal, J. H., Sanacora, G., Blumberg, H., Anand, A., Charney, D. S., Marek, G., Epperson, C. N., Goddard, A., & Mason, G. F. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001021 · Cited by 553
Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo
Do, K. Q., Trabesinger, A. H., Kirsten‐Krüger, M., Lauer, C. J., Dydak, U., Hell, D., Holsboer, F., Boesiger, P., & Cuénod, M. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00229.x · Cited by 540
Purification of serine racemase: Biosynthesis of the neuromodulator d -serine
Wolosker, H., Sheth, K. N., Takahashi, M., Mothet, J.-P., Brady, R. O., Ferris, C. D., & Snyder, S. H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.2.721 · Cited by 524
Sodium-coupled neutral amino acid (System N/A) transporters of the SLC38 gene family
Mackenzie, B., & Erickson, J. D. (2004) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s00424-003-1117-9 · Cited by 515
Efficacy of High-Dose Glycine in the Treatment of Enduring Negative Symptoms of Schizophrenia
Heresco-Levy, U., Javitt, D. C., Ermilov, M., Mordel, C., Silipo, G., & Lichtenstein, M. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.1.29 · Cited by 487
Self-citationKapur, S., & Seeman, P. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001093 · Cited by 459
The Neuropharmacological Basis for the Use of Memantine in the Treatment of Alzheimer's Disease
Rogawski, M. A., & Wenk, G. L. (2003) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2003.tb00254.x · Cited by 436
Goff, D. C., Tsai, G., Levitt, J., Amico, E., Manoach, D., Schoenfeld, D. A., Hayden, D. L., McCarley, R., & Coyle, J. T. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.1.21 · Cited by 436
Lorrain, D. S., Baccei, C. S., Bristow, L. J., Anderson, J. J., & Varney, M. A. (2003) · Neuroscience · doi:10.1016/s0306-4522(02)00652-8 · Cited by 432
Mobile NMDA Receptors at Hippocampal Synapses
Tovar, K. R., & Westbrook, G. L. (2002) · Neuron · doi:10.1016/s0896-6273(02)00658-x · Cited by 431
Anand, A., Charney, D. S., Oren, D. A., Berman, R. M., Hu, X. S., Cappiello, A., & Krystal, J. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.270 · Cited by 426
Philpot, B. D., Sekhar, A. K., Shouval, H. Z., & Bear, M. F. (2001) · Neuron · doi:10.1016/s0896-6273(01)00187-8 · Cited by 414
Glutamate and Depression: Clinical and Preclinical Studies
PAUL, I. A., & SKOLNICK, P. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.016 · Cited by 408
Danysz, W., & Parsons, C. G. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.938 · Cited by 404
Jentsch, J. D., Redmond, D. E., Elsworth, J. D., Taylor, J. R., Youngren, K. D., & Roth, R. H. (1997) · Science · doi:10.1126/science.277.5328.953 · Cited by 398
Cosford, N. D. P., Tehrani, L., Roppe, J., Schweiger, E., Smith, N. D., Anderson, J., Bristow, L., Brodkin, J., Jiang, X., McDonald, I., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm025570j · Cited by 396
Endogenous d‐Serine in Rat Brain: N‐Methyl‐d‐Aspartate Receptor‐Related Distribution and Aging
Hashimoto, A., Nishikawa, T., Oka, T., & Takahashi, K. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb03219.x · Cited by 361
Tsai, G., Lane, H.-Y., Yang, P., Chong, M.-Y., & Lange, N. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.09.012 · Cited by 342
Adler, C. M., Malhotra, A. K., Elman, I., Goldberg, T., Egan, M., Pickar, D., & Breier, A. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.10.1646 · Cited by 337
Matsui, T., Sekiguchi, M., Hashimoto, A., Tomita, U., Nishikawa, T., & Wada, K. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65010454.x · Cited by 334
Differential effects of enrichment on learning and memory function in NR2B transgenic mice
Tang, Y.-P., Wang, H., Feng, R., Kyin, M., & Tsien, J. Z. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00122-8 · Cited by 330
Subunit- and site-specific pharmacology of the NMDA receptor channel
Yamakura, T., & Shimoji, K. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00007-6 · Cited by 311
Metabotropic Glutamate Receptor Subtypes as Targets for Neuroprotective Drugs
Bruno, V., Battaglia, G., Copani, A., D'Onofrio, M., Di Iorio, P., De Blasi, A., Melchiorri, D., Flor, P. J., & Nicoletti, F. (2001) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200109000-00001 · Cited by 311
d-Cycloserine: A ligand for the coupled glycine receptor has partial agonist characteristics
Hood, W. F., Compton, R. P., & Monahan, J. B. (1989) · Neuroscience Letters · doi:10.1016/0304-3940(89)90379-0 · Cited by 308
The Metabotropic Glutamate Receptors: Structure, Activation Mechanism and Pharmacology
Pin, J.-P., & Acher, F. (2002) · Current Drug Target -CNS & Neurological Disorders · doi:10.2174/1568007023339328 · Cited by 294
Molecular mechanisms of glutamate receptor clustering at excitatory synapses
O'Brien, R. J., Lau, L.-F., & Huganir, R. L. (1998) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(98)80062-7 · Cited by 273
The neocortex: An overview of its evolutionary development, structural organization and synaptology
Nieuwenhuys, R. (1994) · Anatomy and Embryology · doi:10.1007/bf00187291 · Cited by 270
MODEL PSYCHOSES AND SCHIZOPHRENIA
LUBY, E. D., GOTTLIEB, J. S., COHEN, B. D., ROSENBAUM, G., & DOMINO, E. F. (1962) · American Journal of Psychiatry · doi:10.1176/ajp.119.1.61 · Cited by 268
Neuroprotection by memantine against neurodegeneration induced by β-amyloid(1–40)
Miguel-Hidalgo, J. J., Alvarez, X. A., Cacabelos, R., & Quack, G. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03731-9 · Cited by 265
PCP (Phencyclidine): Historical and Current Perspectives
Henderson, G. (1982) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(82)91253-6 · Cited by 263
Neuronal and Glial Glycine Transporters Have Different Stoichiometries
Roux, M. J., & Supplisson, S. (2000) · Neuron · doi:10.1016/s0896-6273(00)80901-0 · Cited by 260
Umbricht, D., Koller, R., Vollenweider, F. X., & Schmid, L. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01242-2 · Cited by 258
Tanaka, H., Grooms, S. Y., Bennett, M. V. L., & Zukin, R. S. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02951-6 · Cited by 242
Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia.
Javitt, D. (1987) · PubMed · Cited by 240
Self-citationExcitatory amino acid transporters: keeping up with glutamate
Amara, S. G., & Fontana, A. C. K. (2002) · Neurochemistry International · doi:10.1016/s0197-0186(02)00018-9 · Cited by 240
Chen, L., Muhlhauser, M., & Yang, C. R. (2003) · Journal of Neurophysiology · doi:10.1152/jn.00680.2002 · Cited by 230
d-Serine Added to Clozapine for the Treatment of Schizophrenia
Tsai, G. E., Yang, P., Chung, L.-C., Tsai, I.-C., Tsai, C.-W., & Coyle, J. T. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1822 · Cited by 227
Heidinger, V., Manzerra, P., Wang, X. Q., Strasser, U., Yu, S.-P., Choi, D. W., & Behrens, M. M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-13-05452.2002 · Cited by 223
High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia
Heresco-Levy, U., Ermilov, M., Lichtenberg, P., Bar, G., & Javitt, D. C. (2004) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00707-8 · Cited by 222
Self-citationKinney, G. G., Burno, M., Campbell, U. C., Hernandez, L. M., Rodriguez, D., Bristow, L. J., & Conn, P. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.048702 · Cited by 219
Glutamine Uptake by Neurons: Interaction of Protons with System A Transporters
Chaudhry, F. A., Schmitz, D., Reimer, R. J., Larsson, P., Gray, A. T., Nicoll, R., Kavanaugh, M., & Edwards, R. H. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-01-00062.2002 · Cited by 213
A Placebo-Controlled Pilot Study of the Ampakine CX516 Added to Clozapine in Schizophrenia
Goff, D. C., Leahy, L., Berman, I., Posever, T., Herz, L., Leon, A. C., Johnson, S. A., & Lynch, G. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200110000-00005 · Cited by 209
The NMDA Antagonist Model for Schizophrenia: Promise and Pitfalls
Abi-Saab, W., D'Souza, D., Moghaddam, B., & Krystal, J. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979354 · Cited by 208
LY354740, an mGlu2/3 Receptor Agonist as a Novel Approach to Treat Anxiety/Stress
Schoepp, D. D., Wright, R. A., Levine, L. R., Gaydos, B., & Potter, W. Z. (2003) · Stress · doi:10.1080/1025389031000146773 · Cited by 207
Clark, B. A., & Cull-Candy, S. G. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-11-04428.2002 · Cited by 207
Expression mechanisms underlying long-term potentiation: a postsynaptic view
Nicoll, R. A. (2003) · Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rstb.2002.1228 · Cited by 200
Nacher, J., Rosell, D. R., Alonso‐Llosa, G., & McEwen, B. S. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2000.01424.x · Cited by 200
Adjunctive high-dose glycine in the treatment of schizophrenia
Javitt, D. C., Silipo, G., Cienfuegos, A., Shelley, A.-M., Bark, N., Park, M., Lindenmayer, J.-P., Suckow, R., & Zukin, S. R. (2001) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145701002590 · Cited by 199
Self-citationBenquet, P., Gee, C. E., & Gerber, U. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-22-09679.2002 · Cited by 196
Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial
Tiihonen, J., Hallikainen, T., Ryynänen, O.-P., Repo-Tiihonen, E., Kotilainen, I., Eronen, M., Toivonen, P., Wahlbeck, K., & Putkonen, A. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00524-9 · Cited by 191
Grillon, C., Cordova, J., Levine, L. R., & Morgan, III (2003) · Psychopharmacology · doi:10.1007/s00213-003-1444-8 · Cited by 185
Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans
Krystal, J. H., Karper, L. P., Bennett, A., D'Souza, D. C., Abi-Dargham, A., Morrissey, K., Abi-Saab, D., Bremner, J. D., Bowers Jr., M. B., Suckow, R. F., et al. (1998) · Psychopharmacology · doi:10.1007/s002130050503 · Cited by 184
D-cycloserine added to clozapine for patients with schizophrenia
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.12.1628 · Cited by 182
Johnson, M. P., Baez, M., Jagdmann, G. E., Britton, T. C., Large, T. H., Callagaro, D. O., Tizzano, J. P., Monn, J. A., & Schoepp, D. D. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm034015u · Cited by 182
Spooren, W., Ballard, T., Gasparini, F., Amalric, M., Mutel, V., & Schreiber, R. (2003) · Behavioural Pharmacology · doi:10.1097/01.fbp.0000081783.35927.8f · Cited by 179
Goff, D. C., Henderson, D. C., Evins, A. E., & Amico, E. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00367-9 · Cited by 178
Placebo-Controlled Trial of Glycine Added to Clozapine in Schizophrenia
Evins, A. E., Fitzgerald, S. M., Wine, L., Rosselli, R., & Goff, D. C. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.826 · Cited by 172
Kinney, G. G., Sur, C., Burno, M., Mallorga, P. J., Williams, J. B., Figueroa, D. J., Wittmann, M., Lemaire, W., & Conn, P. J. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-20-07586.2003 · Cited by 172
Pilot controlled trial of d-serine for the treatment of post-traumatic stress disorder
Heresco-Levy, U., Vass, A., Bloch, B., Wolosker, H., Dumin, E., Balan, L., Deutsch, L., & Kremer, I. (2009) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709000339 · Cited by 169
Miyamoto, Y., Yamada, K., Noda, Y., Mori, H., Mishina, M., & Nabeshima, T. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-00750.2001 · Cited by 167
Control of NMDA Receptor Activation by a Glycine Transporter Co-Expressed in Xenopus Oocytes
Supplisson, S., & Bergman, C. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-12-04580.1997 · Cited by 167
Heresco-Levy, U., Ermilov, M., Shimoni, J., Shapira, B., Silipo, G., & Javitt, D. C. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.3.480 · Cited by 167
Self-citationNeuropsychological function in schizophrenia
Nyman, H. (2002) · European Psychiatry · doi:10.1016/s0924-9338(02)80803-3 · Cited by 166
NMDA receptor-mediated dendritic spikes and coincident signal amplification
Schiller, J., & Schiller, Y. (2001) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00217-8 · Cited by 165
Clinical and Sensorimotor Gating Effects of Ketamine in Normals
Duncan, E., Madonick, S. H., Parwani, A., Angrist, B., Rajan, R., Chakravorty, S., Efferen, T. R., Szilagyi, S., Stephanides, M., Chappell, P. B., et al. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00240-2 · Cited by 162
Curran, H. V., & Monaghan, L. (2001) · Addiction · doi:10.1046/j.1360-0443.2001.96574910.x · Cited by 159
A glutamatergic deficiency model of schizophrenia
Carlsson, A., Hansson, L. ‐., Waters, N., & Carlsson, M. L. (1999) · The British Journal of Psychiatry · doi:10.1192/s0007125000293574 · Cited by 153
Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats
Pilc, A., Kłodzińska, A., Brański, P., Nowak, G., Pałucha-Poniewiera, A., Szewczyk, B., Tatarczynska, E., Chojnacka-Wójcik, E., & Wierońska, J. M. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00082-5 · Cited by 151
d-Cycloserine enhances implicit memory in Alzheimer patients
Schwartz, B. L., Hashtroudi, S., Herting, R. L., Schwartz, P., & Deutsch, S. I. (1996) · Neurology · doi:10.1212/wnl.46.2.420 · Cited by 150
Henry, S., Lehmann-Masten, V., Gasparini, F., Geyer, M. A., & Markou, A. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00332-5 · Cited by 146
Ballard, T. M., Pauly-Evers, M., Higgins, G. A., Ouagazzal, A., Mutel, V., Borroni, E., Kemp, J. A., Bluethmann, H., & Kew, J. N. C. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-15-06713.2002 · Cited by 141
Improved Cognition in Alzheimer’s Disease With Short-Term D-Cycloserine Treatment
Tsai, G. E., Falk, W. E., Gunther, J. M., & Coyle, J. T. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.3.467 · Cited by 140
Javitt, D. C., Duncan, L., Balla, A., & Sershen, H. W. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001552 · Cited by 138
Self-citationPałucha-Poniewiera, A., Tatarczynska, E., Brański, P., Szewczyk, B., Wierońska, J. M., Kłak, K., Chojnacka-Wójcik, E., Nowak, G., & Pilc, A. (2003) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.09.006 · Cited by 136
Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder
Heresco-Levy, U., Kremer, I., Javitt, D. C., Goichman, R., Reshef, A., Blanaru, M., & Cohen, T. (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702003061 · Cited by 134 · cited 1×
“001 11.7 0.001 13 0.001 186 Tsai et al (1999) DSER Clozapine 20 2.5 NS 0.8 NS 3.6 NS 98 Goff et al (1999) DCS Conventional 47 23 o.02c — — — NS 187 Heresco-Levy et al (2002) DCS Mixed 21a 14 o.05 — — — NS 188 Goff et al (1999) DCS Clozapine 17a þ 13d o.005 — — — NS 189 —¼not determined; NS¼not…”
InfluentialSelf-citationChronic Elevation of Brain-Derived Neurotrophic Factor by Ampakines
Lauterborn, J. C., Truong, G. S., Baudry, M., Bi, X., LYNCH, G. S., & Gall, C. M. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.053694 · Cited by 132
The N-methyl-d-aspartate receptor, synaptic plasticity, and depressive disorder
Petrie, R. X. A., Reid, I. C., & Stewart, C. A. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00063-2 · Cited by 129
Does glutamate image your thoughts?
Bonvento, G., Sibson, N. R., & Pellerin, L. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(02)02168-9 · Cited by 127
AMPA receptors in epilepsy and as targets for antiepileptic drugs.
Rogawski, M. A., & Donevan, S. D. (1999) · PubMed · Cited by 125
Dursun, S. M., & Deakin, J. F. W. (2001) · Journal of Psychopharmacology · doi:10.1177/026988110101500409 · Cited by 124
Cartmell, J., Monn, J. A., & Schoepp, D. D. (2000) · Psychopharmacology · doi:10.1007/s002130050072 · Cited by 121
Paquet, M., & Smith, Y. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-20-07659.2003 · Cited by 115
Pen, G. L., Kew, J. N. C., Alberati, D., Borroni, E., Heitz, M., & Moreau, J. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00374-3 · Cited by 112
Distribution of mGluR1α and mGluR5 immunolabeling in primate prefrontal cortex
Muly, E. C., Maddox, M., & Smith, Y. (2003) · The Journal of Comparative Neurology · doi:10.1002/cne.10937 · Cited by 110
Heggelund, P., & Hartveit, E. (1990) · Journal of Neurophysiology · doi:10.1152/jn.1990.63.6.1347 · Cited by 106
Javitt, D. C., Balla, A., Burch, S., Suckow, R. F., Xie, S., & Sershen, H. W. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300313 · Cited by 104
Self-citationThe Origin and Turnover of D-Serine in Brain
Dunlop, D. S., & Neidle, A. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6724 · Cited by 100
Preclinical Pharmacology of mGlu2 / 3 Receptor Agonists: Novel Agents for Schizophrenia?
Schoepp, D. D., & Marek, G. J. (2002) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007024606177 · Cited by 100
Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors
Javitt, D. C., Balla, A., Sershen, H. W., & Lajtha, Á. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00237-6 · Cited by 99
Self-citationGlutamate receptor ligands as anxiolytics.
Chojnacka-Wójcik, E., Kłodzińska, A., & Pilc, A. (2001) · PubMed · Cited by 99
The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study
Hársing, L. G., Gacsályi, I., Szabo, G., Schmidt, E., Sziray, N., Sebban, C., Tesolin-Decros, B., Mátyus, P., Egyed, A., Spedding, M., et al. (2003) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(02)01078-x · Cited by 97
Dizocilpine antagonizes the effect of chronic imipramine on learned helplessness in rats
Meloni, D., Gambarana, C., Montis, M. G. D., Pra, P. D., Taddei, I., & Tagliamonte, A. (1993) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(93)90374-3 · Cited by 96
Clozapine Plus Lamotrigine in Treatment-Resistant Schizophrenia
Dursun, S. M., McIntosh, D., & Milliken, H. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.10.950 · Cited by 96
Discovery and SAR of Org 24598—A Selective Glycine Uptake Inhibitor
Brown, A. R., Carlyle, I., Clark, J., Hamilton, W. D., GIBSON, S. G., McGarry, G., McEachen, S., Rae, D. R., Thorn, S. N., & Walker, G. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00355-9 · Cited by 95
Schuster, G., & Schmidt, W. J. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)94825-g · Cited by 95
Aubrey, K. R., & Vandenberg, R. J. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704381 · Cited by 94
van Berckel, B. N. M., Evenblij, C. N., van Loon, B. J., Maas, M. F., van der Geld, M. A. M., Wynne, H. J. A., van Ree, J. M., & Kahn, R. S. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00014-7 · Cited by 93
Lorrain, D. S., Schaffhauser, H., Campbell, U. C., Baccei, C. S., Correa, L. D., Rowe, B. A., Rodriguez, D. E., Anderson, J. J., Varney, M. A., Pinkerton, A. B., et al. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300238 · Cited by 93
Jentsch, J. D., Taylor, J. R., Elsworth, J. D., Redmond, D. E., & Roth, R. H. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00481-3 · Cited by 91
PCP (phencyclidine), historical and current perspectives
Domino, E. F. (1981) · Medical Entomology and Zoology · Cited by 88
Biophysical basis of brain activity: implications for neuroimaging
Shulman, R. G., Hyder, F., & Rothman, D. L. (2002) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583502003803 · Cited by 88
Metabotropic Glutamate Receptors: Potential Drug Targets for the Treatment of Schizophrenia
Chavez-Noriega, L. E., Schaffhauser, H., & Campbell, U. C. (2002) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007023339337 · Cited by 87
Synergistic Interactions between Ampakines and Antipsychotic Drugs
Johnson, S. A., Luu, N. T., Herbst, T., Knapp, R. J., Lutz, D., Arai, A., Rogers, G. A., & LYNCH, G. S. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38148-0 · Cited by 86
Reversal of phencyclidine-induced prepulse inhibition deficits by clozapine in monkeys
Linn, G. S., Negi, S., Gerum, S. V., & Javitt, D. C. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1533-8 · Cited by 84
Self-citationPapp, M., & Moryl, E. (1996) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00675-9 · Cited by 81
Shirao, T., & Sekino, Y. (2001) · Neuroscience Research · doi:10.1016/s0168-0102(01)00209-7 · Cited by 80
Kwon, Y. H., Esguerra, M., & Sur, M. (1991) · Journal of Neurophysiology · doi:10.1152/jn.1991.66.2.414 · Cited by 79
Balla, A., Sershen, H. W., Serra, M., Koneru, R., & Javitt, D. C. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300019 · Cited by 77
Self-citationDebler, E. A., & Lajtha, Á. (1987) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1987.tb05747.x · Cited by 76
Neuron-astrocyte interactions: implications for cellular energetics and antioxidant levels.
Aschner, M. (2000) · PubMed · Cited by 75
Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics
Evins, A. E., Amico, E. T., Shih, V., & GOFF, D. C. (1997) · Journal of Neural Transmission · doi:10.1007/bf01291892 · Cited by 74
Javitt, D. C., Sershen, H., Hashim, A., & Lajtha, A. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00047-x · Cited by 74
Self-citationTakanaga, H., Tokuda, N., Ohtsuki, S., Hosoya, K., & Terasaki, T. (2002) · Molecular Pharmacology · doi:10.1124/mol.61.6.1289 · Cited by 74
Marenco, S., Egan, M. F., Goldberg, T. E., Knable, M. B., McClure, R. K., Winterer, G., & Weinberger, D. R. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00311-5 · Cited by 73
Javitt, D. C., & Frusciante, M. J. (1997) · Psychopharmacology · doi:10.1007/s002130050168 · Cited by 70
Self-citationSerotonergic Agents That Activate 5HT2A Receptors Prevent NMDA Antagonist Neurotoxicity
Farber, N. B., Hanslick, J., Kirby, C., McWilliams, L., & Olney, J. W. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00127-9 · Cited by 70
Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice
Brody, S. A., Conquet, F., & Geyer, M. A. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1635-3 · Cited by 68
Ketamine–Can Chronic Use Impair Memory
Jansen, K. L. R. (1990) · International Journal of the Addictions · doi:10.3109/10826089009056204 · Cited by 66
Rivadulla, C., Sharma, J., & Sur, M. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-05-01710.2001 · Cited by 65
The NMDA-receptor antagonist MK-801 selectively disrupts reversal learning in rats
van der Meulen, J. A. J., Bilbija, L., Joosten, R. N. J. M. A., de Bruin, J. P. C., & Feenstra, M. G. P. (2003) · Neuroreport · doi:10.1097/00001756-200312020-00018 · Cited by 65
PROCTER, A. W., Stirling, J. M., Stratmann, G. C., Cross, A. J., & Bowen, D. M. (1989) · Neuroscience Letters · doi:10.1016/0304-3940(89)90441-2 · Cited by 64
NMDA-induced phosphorylation and regulation of mGluR5
Alagarsamy, S., Rouse, S. T., Junge, C., Hubert, G. W., Gutman, D. A., Smith, Y., & Conn, P. J. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(02)00826-2 · Cited by 63
Balla, A., Koneru, R., Smiley, J., Sershen, H., & Javitt, D. C. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00230-5 · Cited by 62
Self-citationJentsch, J. D., Roth, R. H., & Taylor, J. R. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00926-4 · Cited by 62
Phencyclidine (PCP)-induced deficits of prepulse inhibition in monkeys
Linn, G. S., & Javitt, D. C. (2001) · Neuroreport · doi:10.1097/00001756-200101220-00031 · Cited by 61
Self-citationMakino, C., Fujii, Y., Kikuta, R., Hirata, N., Tani, A., Shibata, A., Ninomiya, H., Tashiro, N., Shibata, H., & Fukumaki, Y. (2002) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.10041 · Cited by 59
The PCP Psychosis: Prolonged Intoxication or Drug-Precipitated Functional Illness?
Erard, R. E., Luisada, P. V., & Peele, R. (1980) · Journal of Psychedelic Drugs · doi:10.1080/02791072.1980.10471432 · Cited by 58
Swanson, C. J., & Schoepp, D. D. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.038422 · Cited by 58
The psychotropic effects of cycloserine: A new use for an antibiotic
Crane, G. E. (1961) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(61)80007-2 · Cited by 55
Stewart, C. A., & Reid, I. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001014 · Cited by 53
D-Cycloserine Treatment of Alzheimer Disease
RANDOLPH, C. C., Roberts, J. W., Tierney, M. C., Bravi, D., Mouradian, M. M., & Chase, T. N. (1994) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199408030-00006 · Cited by 53
Tatarczynska, E., Pałucha-Poniewiera, A., Szewczyk, B., Chojnacka-Wójcik, E., Wierońska, J. M., & Pilc, A. (2002) · PubMed · Cited by 53
Evaluation of Cycloserine in the Treatment of Alzheimer's Disease
Fakouhi, T. D., Jhee, S. S., Sramek, J. J., Benes, C. O., Schwartz, P., Hantsburger, G., Herting, R. L., Swabb, E. A., & Cutler, N. R. (1995) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198879500800405 · Cited by 51
Effects of phencyclidine, ketamine and MDMA on complex operant behavior in monkeys
Thompson, D. M., Winsauer, P. J., & Mastropaolo, J. P. (1987) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(87)90136-5 · Cited by 49
Suppiramaniam, V. D., Bahr, B. A., Sinnarajah, S., Owens, K., Rogers, G. A., Yilma, S., & Vodyanoy, V. J. (2001) · Synapse · doi:10.1002/syn.1037 · Cited by 44
Psychiatric uses of antiepileptic treatments
Boylan, L. S., Devinsky, O., Barry, J. J., & Ketter, T. A. (2002) · Epilepsy & Behavior · doi:10.1016/s1525-5069(02)00501-7 · Cited by 43
Bohn, I., Giertler, C., & Hauber, W. (2003) · Cerebral Cortex · doi:10.1093/cercor/13.9.968 · Cited by 41
The role of glutamate receptors in antipsychotic drug action
Ossowska, K., Pietraszek, M., Wardas, J., Nowak, G., Zajaczkowski, W., Wolfarth, S., & Pilc, A. (2000) · Amino Acids · doi:10.1007/s007260070037 · Cited by 40
Silent glutamatergic synapses in the mammalian brain
Isaac, J. T. R., Nicoll, R. A., & Malenka, R. C. (1999) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y99-075 · Cited by 38
Effects of phencyclidine on prepulse inhibition of acoustic startle response in the macaque
Javitt, D. C., & Lindsley, R. W. (2001) · Psychopharmacology · doi:10.1007/s002130100758 · Cited by 37
Self-citationChronic high-dose glycine nutrition: effects on rat brain cell morphology
Shoham, S., Javitt, D. C., & Heresco‐Levy, U. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01046-5 · Cited by 36
Self-citationEffects of the mGlu2/3 receptor agonist LY379268 on motor activity in phencyclidine-sensitized rats
Clark, M., Johnson, B. G., Wright, R. A., Monn, J. A., & Schoepp, D. D. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(02)00848-1 · Cited by 35
CX-516 Cortex pharmaceuticals.
Danysz, W. (2002) · PubMed · Cited by 34
Melone, M., Bragina, L., & Conti, F. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001193 · Cited by 34
Behavioral effects of chronic phencyclidine in monkeys
Linn, G. S., O’Keeffe, R. T., Schroeder, C. E., Lifshitz, K., & Javitt, D. C. (1999) · Neuroreport · doi:10.1097/00001756-199909090-00017 · Cited by 34
Self-citationAbe, K., & Misawa, M. (2002) · Neuroscience Research · doi:10.1016/s0168-0102(02)00190-6 · Cited by 33
A novel alanine-insensitive d-serine transporter in rat brain synaptosomal membranes
Javitt, D. C., Balla, A., & Sershen, H. W. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02557-x · Cited by 31
Self-citationEffects of dofetilide on cardiovascular tissues from normo- and hypertensive rats
Doggrell, S. A., & Nand, V. (2002) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357021778862 · Cited by 30
Inhibition of striatal dopamine release by glycine and glycyldodecylamide
Javitt, D. C., Sershen, H. W., Hashim, A., & Lajtha, Á. (2000) · Brain Research Bulletin · doi:10.1016/s0361-9230(00)00258-6 · Cited by 26
Self-citationMaeda, J., Suhara, T., Okauchi, T., & Semba, J. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(02)01261-2 · Cited by 23
Thompson, D. M., & Moerschbaecher, J. M. (1984) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(84)90313-7 · Cited by 19
High dose glycine nutrition affects glial cell morphology in rat hippocampus and cerebellum
Shoham, S., Javitt, D. C., & Heresco‐Levy, U. (1999) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145799001285 · Cited by 19
Self-citationHársing, L. G., Sólyom, S., & Salamon, C. (2001) · Neurochemical Research · doi:10.1023/a:1012328300037 · Cited by 18
Ellison, G. D., Keys, A. S., & Noguchi, K. (1999) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1999.tb02104.x · Cited by 17
Long-term imipramine effects are prevented by NMDA receptor blockade.
Demontis, M., Gambarana, C., Meloni, D., Taddei, I., & Tagliamonte, A. (1993) · Brain Research · doi:10.1016/0006-8993(93)91570-i · Cited by 17
Riekkinen, P., Ikonen, S., & Riekkinen, M. (1998) · Neuroreport · doi:10.1097/00001756-199811160-00016 · Cited by 15
Research works printed but not linked: 9
- Gomeza J, Ohno K, Betz H . Glycine transporter isoforms in the mammalian central nervous system: structures, functions and therapeutic promises. Curr Opin Drug Discov Devel 2003; 6: 675–682.
- Yamomoto N, Tomita U, Umino A, Kaneda K, Kawaguchi N, Iwama H et al. Uptake and release of [3H]D-serine in the synaptosomal P2 fraction prepared from the rat cerebral cortex. Neurochem Res 2001; 26: 285.
- Javitt DC, Zukin SR . Mechanisms of phencyclidine (PCP)-N-methyl-D-asparate (NMDA) receptor interaction: implications for schizophrenia. In: Tamminga CA, Schulz SC (eds). Raven Press: New York, 1991 pp 13–20.
- Coyle JT, Tsai G, Bergeron R, Martina M, Berger-Sweeney J . Gene Knockout Study of Glycine Transporter I. Program No. 373.15.2003 Abstract Viewer/Itinerary Planner. Society for Neuroscience: Washington, DC, 2003 Online. 2003.
- Pietraszek M, Golembiowska K, Bijak M, Ossowska K, Wolfarth S . Differential effects of chronic haloperidol and clozapine administration on glutamatergic transmission in the fronto-parietal cortex in rats: microdialysis and electrophysiological studies. Naunyn Schmiedebergs Arch Pharmacol 2002; 366: 417–424. · doi:10.1007/s00210-002-0619-x
- Toth E, Weiss B, Banay-Schwartz M, Lajtha A . Effect of glycine derivatives on behavioral changes induced by 3-mercaptopropionic acid or phencyclidine in mice. Res Comm Psychol Psychiat Behav 1986; 11: 1–9.
- Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 2000; 57: 270–276. · DOI · Paper page
- Pilc A . LY-354740 (Eli Lilly). IDrugs 2003; 6: 66–71.
- Heresco-Levy U . Clnical trials with glycine site agonists of the NMDA receptor used as adjuvants to conventional and atypical antipsychotics. Int J Neuropsychopharmacol 2004; 7: S25.
Cited by
The mismatch negativity: a review of underlying mechanisms
Garrido, M. I., Kilner, J. M., Stephan, K. E., & Friston, K. J. (2009) · Clinical Neurophysiology · doi:10.1016/j.clinph.2008.11.029 · Cited by 1,441
“This is important because the critical role of the NMDA receptor in the plasticity of glutamatergic synapses is at the core of current pathophysiological theories of schizophrenia (Friston and Frith, 1995; Harrison and Weinberger, 2005; Javitt, 2004; Stephan et al., 2006).”
BackgroundMoghaddam, B., & Javitt, D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.181 · Cited by 1,035
Self-citationThe Postsynaptic Architecture of Excitatory Synapses: A More Quantitative View
Sheng, M., & Hoogenraad, C. C. (2007) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.76.060805.160029 · Cited by 1,003
Ethological and temporal analyses of anxiety-like behavior: The elevated plus-maze model 20 years on
Carobrez, A. P., & Bertoglio, L. J. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.04.017 · Cited by 1,005
Drug resistance in brain diseases and the role of drug efflux transporters
Löscher, W., & Potschka, H. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1728 · Cited by 900
Metadata
- Authors
- Javitt, D. C.
- Venue
- Molecular Psychiatry
- Published
- 2004-07-27
- Volume
- 9
- Issue
- 11
- Pages
- 984-997
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2052480734
- Cited by
- 524
- References
- 185
- FWCI
- 11.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.